Updated data from a single-arm, open-label, multicentre clinical study on the efficacy and safety of surufatinib combined with EP regimen and serplulimab in first-line treatment of NEC

#4399

Introduction: NEC is an aggressive neuroendocrine neoplasm with limited treatment options. Surufatinib (SUR), a kinase inhibitor targeting VEGFRs, FGFR-1, and CSF-1R, improves vascular normalisation and tumour microenvironment, synergising with chemo- and immunotherapy.

Aim(s): To evaluate the efficacy and safety of SUR plus the EP regimen and Serplulimab (SER) as a first-line treatment for patients (pts) with advanced or metastatic NEC.

Materials and methods: Pts with advanced/metastatic NEC naive to systemic therapy were enrolled. In phase Ib, pts received SUR (250 mg, QD, PO, Q3W) plus EP regimen (etoposide injection: 100mg/m2, d1-3, IV, Q3W; cisplatin: 25mg/m2, d1-3, IV, Q3W) and SER (300mg, d1, IV, Q3W) for a maximum of six cycles, followed by a maintenance phase of SUR plus SER. In phase II, pts received the same treatment regimen. The primary endpoint was PFS, while secondary endpoints included ORR, DCR, OS, and safety.

Conference:

Presenting Author: Lin Z

Authors: Zhang T, Lin Z, Zhao L, Ma H, Zhang D,

Keywords: NEC, surufatinib, EP, first-line,